A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...

Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oc ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

Indigenous communities in Latin America say they are missing out on life-saving HIV drugs due to a lack of representation.

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

Cases of HIV amongst heterosexual patients in England has risen by more than 30% since 2022. Data from the UKHSA found that ...

1 The phase 3 PURPOSE 2 trial is assessing lenacapavir as a pre-exposure prophylaxis (PrEP) medicine to reduce the chance of getting HIV through sex, comparing it when taken twice per year as PrEP ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

HIV prevention data will include an analysis of newly initiated pre-exposure prophylaxis (PrEP) use in priority populations with unmet needs for PrEP in the U.S. Additional HIV research findings ...

Chaphalkar, PhD.New research reveals that doxycycline post-exposure prophylaxis raises resistance gene levels in the gut, but ...

Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...